Save Product
Product Details
Synonym
TNFRSF17, CD269, BCM, BCMA
Source
FITC-Labeled Human BCMA, His Tag (BCA-HF2H3) is produced via conjugation of FITC to Human BCMA, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human BCMA, His Tag is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 54 (Accession # Q02223-1).
Predicted N-terminus: Met 1
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
Conjugate
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Evaluation of CAR expression
FACS Analysis of Anti-BCMA CAR Expression
2e5 of 293 CAR cells transfected with anti-BCMA-scFv were stained with 100 μL of 1 μg/mL of FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H3) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A), FITC signal was used to evaluate the binding activity (QC tested).
ProtocolFACS Analysis of Non-specific binding to PBMCs
5e5 of PBMCs were stained with FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H3) and anti-CD3 antibody, washed and then analyzed with FACS. PE signal was used to evaluate the expression of CD3+ T cells in PBMCs, and FITC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
B-cell maturation protein
- Category：
- Approved Drugs：
7 Details
- Drugs in Clinical Trials：
117 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing